Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 87

Alexion Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Alexion Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alexion Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Alexion Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Alexion Pharmaceuticals, Inc. - Brief Alexion Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alexion Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alexion Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alexion Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Alexion Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alexion Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alexion Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alexion Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alexion Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Alexion Pharmaceuticals, Inc.; Alexion Pharmaceuticals, Inc. - Key Therapeutics; Alexion Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Alexion Pharmaceuticals, Inc. - News; Alexion Pharmaceuticals, Inc. - Latest Updates; Alexion Pharmaceuticals, Inc. - Pipeline; Alexion Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Alexion Pharmaceuticals, Inc. Snapshot
Alexion Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Alexion Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Alexion Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Alexion Pharmaceuticals, Inc. – Pipeline Products Glance
Alexion Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Alexion Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Alexion Pharmaceuticals, Inc. – Drug Profiles
ALXN1007
Product Description
Mechanism of Action
R&D Progress
ALXN1102
Product Description
Mechanism of Action
R&D Progress
Asfotase Alfa
Product Description
Mechanism of Action
R&D Progress
cPMP Replacement Therapy
Product Description
Mechanism of Action
R&D Progress
mAb171
Product Description
Mechanism of Action
R&D Progress
Samalizumab
Product Description
Mechanism of Action
R&D Progress
Soliris
Product Description
Mechanism of Action
R&D Progress
TA106
Product Description
Mechanism of Action
R&D Progress
TT31
Product Description
Mechanism of Action
R&D Progress
TT32
Product Description
Mechanism of Action
R&D Progress
TT33
Product Description
Mechanism of Action
R&D Progress
Alexion Pharmaceuticals, Inc. – Pipeline Analysis
Alexion Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Alexion Pharmaceuticals, Inc. – Pipeline Products By Target
Alexion Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Alexion Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Alexion Pharmaceuticals, Inc. – Recent Pipeline Updates
Alexion Pharmaceuticals, Inc. - Dormant Projects
Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Pexelizumab
Alexion Pharmaceuticals, Inc. – Company Statement
Alexion Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Alexion Pharmaceuticals, Inc., Recent Developments
Alexion Pharmaceuticals, Inc.- Press Release
Mar 29, 2012: Alexion Presents Positive Phase II Data Of Asfotase Alfa At ACMG Annual Meeting
Mar 07, 2012: New England Journal of Medicine Publishes Data From Phase II Study Of Asfotase Alfa In Hypophosphatasia
Dec 06, 2009: Soliris Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders
Nov 10, 2009: Taligen Announces That TT30, A Novel Protein Targeting The Complement System, Will Be Highlighted In Two Presentations At The American Society Of Hematology Meeting
Nov 02, 2009: Enobia Initiates Phase II Clinical Study Of ENB-0040 For Hypophosphatasia
Sep 14, 2009: Enobia Announces Positive Clinical Results Of ENB-0040 For Hypophosphatasia
Aug 06, 2009: European Commission and U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
Aug 06, 2009: European Commission And U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation For The Treatment Of Atypical Hemolytic Uremic Syndrome (aHUS)
Aug 06, 2009: European Commission and U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS).
Jun 10, 2009: Alexion's Soliris Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
May 28, 2009: Researchers to Report on the Investigational Use of Alexion's Soliris (Eculizumab) to Prevent Antibody-Mediated Rejection in High-Risk Kidney Transplant Patients
Feb 25, 2009: Alexion's Soliris (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH
Feb 25, 2009: Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH.
Jan 29, 2009: Alexion's Soliris (eculizumab) Receives Marketing Approval in Canada for All Patients with PNH
Jan 29, 2009: Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Canada for All Patients with PNH.
Jan 29, 2009: New England Journal Of Medicine Publishes Case Reports On The Investigational Use of Soliris(Eculizumab) In Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Jan 12, 2009: Soliris Receives Orphan Drug Designation in Japan
Jan 12, 2009: Soliris(R) Receives Orphan Drug Designation in Japan.
Financial Deals Landscape
Alexion Pharmaceuticals, Inc., Deals Summary
Alexion Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Alexion Acquires Patents Of An Investigational Therapy For Infants From Orphatec
Alexion Pharma Acquires Rights Of Soliris From OMRF
Alexion Pharma Acquires Dow Manufacturing Facility From Dow Chemical
Licensing Agreements
Alexion Pharma Enters Into Licensing Agreement With PDL BioPharma
Equity Offering
Alexion Pharma Completes Public Offering Of $148.35 Million
Alexion Pharma Completes Public Offering Of $66.87 Million
Alexion Pharma Completes Public Offering Of $85.25 Million
Debt Offering
Alexion Pharma Completes Private Placement Of 1.375% Notes For $150 Million
Acquisition
Alexion Pharma Completes Acquisition Of Enobia Pharma
Alexion Pharma Acquires Taligen Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Alexion Pharmaceuticals, Inc., Key Information
Alexion Pharmaceuticals, Inc., Key Facts
Alexion Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Alexion Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Alexion Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Alexion Pharmaceuticals, Inc. – Phase II, 2012
Alexion Pharmaceuticals, Inc. – Phase I, 2012
Alexion Pharmaceuticals, Inc. – Pre-Clinical, 2012
Alexion Pharmaceuticals, Inc. – Discovery, 2012
Alexion Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Alexion Pharmaceuticals, Inc. - Pipeline By Target, 2012
Alexion Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Alexion Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Alexion Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Alexion Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Alexion Pharmaceuticals, Inc., Other Locations
Alexion Pharmaceuticals, Inc., Subsidiaries
Alexion Pharmaceuticals, Inc., Deals Summary
Alexion Acquires Patents Of An Investigational Therapy For Infants From Orphatec
Alexion Pharma Acquires Rights Of Soliris From OMRF
Alexion Pharma Acquires Dow Manufacturing Facility From Dow Chemical
Alexion Pharma Enters Into Licensing Agreement With PDL BioPharma
Alexion Pharma Completes Public Offering Of $148.35 Million
Alexion Pharma Completes Public Offering Of $66.87 Million
Alexion Pharma Completes Public Offering Of $85.25 Million
Alexion Pharma Completes Private Placement Of 1.375% Notes For $150 Million
Alexion Pharma Completes Acquisition Of Enobia Pharma
Alexion Pharma Acquires Taligen Therapeutics

List of Figures
Alexion Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Alexion Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Alexion Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Alexion Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Alexion Pharmaceuticals, Inc. - Pipeline By Target, 2012
Alexion Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Alexion Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• Abbott Laboratories - IT Sales Opportunities - 2009